Pfiz­er ex­pands la­bel for block­buster BRAF/MEK com­bo in­to lung can­cer

Pfiz­er’s $11.4 bil­lion 2019 ac­qui­si­tion of Ar­ray Bio­Phar­ma and its can­cer drugs Braftovi and Mek­tovi is pay­ing off again, this time with an ex­pand­ed la­bel for metasta­t­ic non-small cell lung can­cer (NSCLC) with a BRAF V600E mu­ta­tion.

The FDA ap­proved the com­bi­na­tion of Braftovi (en­co­rafenib), a BRAF in­hibitor, and Mek­tovi (binime­tinib), a MEK in­hibitor, yes­ter­day af­ter­noon based on da­ta from the Phase II PHAROS study that in­ves­ti­gat­ed the com­bo ther­a­py in both treat­ment-naïve and pre­vi­ous­ly treat­ed pa­tients with the mu­tat­ed NSCLC.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER